Genesis Consortium
VC Fund
Genesis Consortium is an alliance of venture funds and corporations to promote human and planetary health.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Genesis Consortium invests in
Stages Genesis Consortium invests in
Countries Genesis Consortium invests in
Round sizes
Round size
- Seed
- $525k–$3.6M
Investment Focus
Industry
- Biotechnology 4 (57%)
- Fashion 1 (14%)
- Biopharma 1 (14%)
- Health Care 1 (14%)
- Architecture 1 (14%)
Stage
- Seed 6 (86%)
- Pre-Seed 1 (14%)
Country
- United States 5 (71%)
- Turkey 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Developing increasingly challenging vaccine targets requires increasingly sophisticated technologies. Over the last century, vaccines have made essential contributions to the doubling of human life expectancy. Calder engineers next-generation vaccines that will further protect against the most intractable and life-threatening viruses. Viruses haveevolved to become shapeshifters that can evade and distract our immune system by hiding some of their most vulnerable sites. History has shown that pandemics are not only lethal but also inevitable. Currently, the vaccines we know best poorly protect against pandemics and other viral outbreaks and leave many at-risk populations unprotected. By combining structure-based design as part of a novel manufacturing process, Calder’s unique 3D-Vaxlock technology generates molecular staples that lock vaccines into their most potent shape. Their initial focus is on generating a universal flu vaccine that protects against all seasonal strains and an RSV vaccine specifically for the elderly. With this platform, they have the ability to create treatments that better protect against life-threatening diseases with exceptional safety, efficacy, and durability. Calder’s next generation vaccines will prevent severe disease and deaths, alleviate a substantial burden on the healthcare system, and allow billions of people to lead healthy lives. | $625K / Seed / Sep 12, 2023 | ||
| Wayfinder Biosciences is a biotechnology company developing orally available small molecule drugs that modulate the function of the RNAs encoding key disease targets. The company's proprietary platform combines unique screening and computational technologies to rapidly discover potent, selective and biologically active RNA-targeting smallmolecules. Wayfinder's programs are focused on traditionally inaccessible targets in oncology and neurodegenerative disease. Wayfinder Biosciences was established in 2021 and is headquartered in Seattle, WA. | $3.6M / Seed / Oct 17, 2022 | ||
| Gozen Bioworks is a bio-tech company that invents and develops next-gen microbe-derived biomaterials. | $525K / Seed / Sep 21, 2022 | ||
| MAA’VA™ is developing a proprietary sustainable carbon negative construction material, turning plastic and nonplastic waste into eco-material, advancing solutions to climate change crisis, waste crisis, global river sand shortage, water scarcity and rapid urbanization. Our eco-concrete can be used for both conventional and 3D printingconstruction. By optimizing 3D printing technology we can build environmentally friendly low cost housing with eco-concrete in one day for 1/10th of the construction cost and half of the construction waste. | $525K / Seed / Sep 21, 2022 | ||
| west~bourne is creating the next-generation go-to brand for plant powered and planet positive provisions. | $525K / Seed / Sep 21, 2022 | ||
| Mirá is launching a biofuel breakthrough to subvert coal dependency in heavy industries. | $525K / Seed / Sep 21, 2022 | ||
| See all 7 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Genesis Consortium invest in?
Genesis Consortium invests primarily in Biotechnology, Fashion and Biopharma startups, most often at Seed and Pre-Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Genesis Consortium invest in?
Genesis Consortium typically joins rounds of $525k–$3.6M at Seed. These are whole funding-round sizes, not Genesis Consortium's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Genesis Consortium took part in.
When did Genesis Consortium last invest?
The most recent investment recorded for Genesis Consortium closed in Sep 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
